The stocks listed here have all been struggling due to weak demand. They are cheap-looking buys that investors haven't been ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

The impact of this deal on the stock market has been quite bullish, especially for AI-related companies and those involved in ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...

BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

President Donald Trump talked up a joint venture investing up to $500 billion for infrastructure tied to AI by a new ...